Guilford Gliadel First-Line Use: Data Stratification To Be Considered By Cmte.

Guilford's Gliadel Wafer stratification of clinical results will be considered by FDA's Oncologic Drugs Advisory Committee in its review of the drug for first-line treatment of malignant glioma, originally scheduled for Sept. 11.